+

WO1982003773A1 - Solution de dialyse contenant du glucose, des acides amines et de l'insuline - Google Patents

Solution de dialyse contenant du glucose, des acides amines et de l'insuline Download PDF

Info

Publication number
WO1982003773A1
WO1982003773A1 PCT/US1982/000365 US8200365W WO8203773A1 WO 1982003773 A1 WO1982003773 A1 WO 1982003773A1 US 8200365 W US8200365 W US 8200365W WO 8203773 A1 WO8203773 A1 WO 8203773A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
amino acids
insulin
liter
meq
Prior art date
Application number
PCT/US1982/000365
Other languages
English (en)
Inventor
Travenol Lab Inc Baxter
Robert K Ausman
Original Assignee
Baxter Travenol Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Lab filed Critical Baxter Travenol Lab
Priority to AU83923/82A priority Critical patent/AU8392382A/en
Publication of WO1982003773A1 publication Critical patent/WO1982003773A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor

Definitions

  • peritoneal dialysis solution is inserted into the peritoneal cavity, whereby diffu ⁇ sion exchange takes place between the solution and the bloodstream across the natural body membranes, to remove by diffusion the waste products which are normally ex- creted through the kidneys, typically solutes such as sodium and chloride ions, and other materials normally excreted by the body such as urea and creatinine, and also water.
  • the nature and rate of the materials removed from the body by peritoneal dialysis is a function of the sol ⁇ utes present in the peritoneal dialysis solution.
  • Phy ⁇ siological salts are present in the peritoneal dialysis solution, such as sodium chloride, sodium lactate, and sodium acetate, generally at slightly hypotonic concen- trations (but for calcium) so that excess concentrations of the ions forming such salts in the bloodstream will diffuse into the peritoneal dialysis solution for removal.
  • solutes may be added to generate the nec ⁇ essary osmotic pressure.
  • this solute is a sugar such as glucose, which may normally be present in peritoneal dialysis solutions in a concentration of about 0.5 to 4.25 percent by weight.
  • peritoneal dialysis solution diffuses into the bloodstream to a significant extent. Accordingly, while the system is safe and effective for increasing the ultrafiltration dur ⁇ ing peritoneal dialysis, the patient receives a heavy dose of calories during each peritoneal dialysis procedure from
  • ingredients of the solution of this invention are all individually known as ingredients of parenteral
  • the addition of insulin to the solution provides benefits relating to both the metabolizing of glucose, and also the assimila ⁇ tion of amino acids into the cells to form a protein. While these are known functions of insulin, it has not been previously used as a combined ingredient in a dialy- sis solution to simultaneously facilitate the metabolizing of amino acids and glucose or other sugar by the patient.
  • measured amounts of amino acids and glucose or other sugar may be used in the peritoneal dialysis solution, initially for the purpose of increasing the osmolarity of the solution so that ultrafiltration of water may take place from the patient during the dialysis procedure.
  • the insulin serves to facilitate the metabolizing of glucose and amino acids which diffuse from the dialysis solution into the bloodstream of the patient.
  • the amount of insulin required can be predetermined beforehand, depending upon the concentrations of amino acids and sugar present, so that a premeasured solution may be provided for a dialysis procedure, for the combined benefits of dialyzing uremic patients who are diabetic and protein starved, so that the patients receive the optimum amount of insulin to f cilitate their metabolism of the amino acids and sugar provided, without the need in the case of diabetic patients to recalculate their normal administra ⁇ tion schedule of insulin. Also, less sugar may be used, being partly or completely replaced by amino acids.
  • a medical solution for administration to patients, typically for use as a dialysis solution. It comprises a water solution having the presence of physiological salts in sufficient concentration to be osmotically compatible with blood. There is also included a mixture of physiological amino acids, and optionally a source of carbohydrate nutrition such as glucose is present. There is also added insulin in proportions sufficient to permit the substantial assimilation of both the source of carbohy ⁇ drate nutrition when present, and amino acids by a dia ⁇ betic or other type of patient. If desired, other sugars such as fructose may be used as an equivalent substitute for glucose. Also glucose polymers and the like, or a sugar alcohol such as glycerol may be used as the source of carbohydrate nutrition.
  • glucose as used below is intended to include these equivalent materials as alternatives.
  • the solution is particularly contemplated for use as a peritoneal dialysis solution where a relatively high osmolarity is desirable to stimulate ultrafiltration of water from a patient, but it may also be used as an intra- venous nutrient solution or a he odialysis solution.
  • the mixture of glucose and amino acids serves as an osmolarity-promoting agent to provide higher ultrafiltration.
  • the amino acids, glucose, and insulin diffuse into the bloodstream of the patient.
  • the glucose and amino acids pro ⁇ vide nutrition to the patient, with the assimilation of the glucose and amino acids being facilitated by the presence of insulin to help reverse the typically negative nitrogen balance found in persons in renal failure while treated under prior art procedures.
  • the solution also assists in the management of diabetic patients, since the premeasured amount of insulin present in the medical solution facilitates the assimila ⁇ tion of the glucose present without the diabetic patient having to change the normal regime of his prescribed dosage of insulin taken conventionally.
  • the patient's entire insulin requirements can be taken care of by the insulin in the solution of this invention, if desired, to reduce the numbers of injections that the patient must subject himself to in the instance that the patient is engaging in a continuous and daily regime of CAPD, with several changes of dialysis solution being made every day.
  • solutions of this invention may be premixed, typ- ically with a separate sterilization of different solution portions containing respectively the glucose and amino acids in a separate, interconnected container system, followed by mixing without breaching the sterile conditions of the system. This avoids the known incompatability problems encountered on sterilizing a mixture of sugar
  • glucose and amino acid solutions may be separately sterilized in separate containers, and then brought together by the use of a sterile connector system similar to that shown in U.S. Patent No. 4,157,723 or the like, providing a reliably sterile connection per ⁇ mitting the sterile mixing of the two solutions to form the medical solution of this invention.
  • glucose and amino acid solutions may be premixed shortly before infusion under conditions which are substantially aseptic although not necessarily completely sterile.
  • from 0.5 to 4 grams per liter of glucose or an equivalent material may be present in the solution of this invention, in conjunction with from 1 to 4 grams per liter of a mixture of amino acids preferably containing at least 50 percent by weight of essential amino acids, optionally including other nonessential amino acids as may be desired.
  • a mixture of amino acids preferably containing at least 50 percent by weight of essential amino acids, optionally including other nonessential amino acids as may be desired.
  • the mixture of amino acids found in Travasol® amino acid solutions sold by Travenol Laboratories, Inc. of Deerfield, Illinois may be utilized to formulate the solutions of this invention, or any other available mixture of amino acids for parenteral administration may be used.
  • Added to this may preferably be 1 to 10 units of insulin per liter of solution for the beneficial purposes described above.
  • amino acids is intended to include suitable short-chain polypeptides as equivalent substitute materials for the free amino acids.
  • concentration of glucose can be re ⁇ substituted in this manner from a typical high glucose concen ⁇ tration of up to 4.25 percent as found in prior art solutions, while the osmolarity of the solution can remain elevated because of the presence of the amino acid.
  • a dialysis solution having the desired high osmolarity coupled with a better nutrient mix for the patient, may be provided in which the nutrients are better assimilated or metabolized by the patient because of the presence of the insulin.
  • the medical solution of this invention may comprise a water solution at a pH of 5.0 to 7.4, con ⁇ taining from 130 to 140 mEq/liter of sodium, 100 to 140 mEq/liter of chloride, 0 to 6 mEq/liter of calcium, 0 to 4 mEq/liter of magnesium, and, if desired, other ions, for example, 30 to 40 mEq/liter of bicarbonate precursors such as one or more of lactate, acetate, malate, and/or succinate ions.
  • the above ions may be provided by the addition of conventional physiological salts such as sodium chloride, calcium chloride, sodium lactate, sodium acetate, and traces of other salts such as potassium chloride, magne ⁇ sium chloride, and the like, added in accordance with the known requirements for proper ion balance in a dialysis solution.
  • physiological salts such as sodium chloride, calcium chloride, sodium lactate, sodium acetate, and traces of other salts such as potassium chloride, magne ⁇ sium chloride, and the like, added in accordance with the known requirements for proper ion balance in a dialysis solution.
  • the osmolarity of the solutions of this invention is generally preferable for the osmolarity of the solutions of this invention to be from 272 to 700 milliosmols per liter, preferably 279 to 480 milliosmols per liter.
  • the bicarbonate precursor acid ions mentioned above, as well as other acid ions of the Krebs cycle, may be added to also offer advantages in pH control of the peri ⁇ toneal dialysis solution of this invention.
  • the sodium or potassium salts of such ions, for exmaple, may be used for this purpose, or the free acids.
  • Sulfhydryl-type antioxidants for example N-acyl cysteine, may be also added to stabilize the amino acids in the peritoneal dialysis solution of this invention.
  • a peritoneal dialysis solution in ac ⁇ cordance with this invention may be provided by adding, per liter of water, 5.55 grams of sodium chloride, 3.92 grams of sodium lactate, 0.257 gram of calcium chloride dihydrate, 0.152 gram of magnesium chloride hexahydrate, 1 gram of glucose, 3.25 grams of a mixture of essential and other amino acids, and 3 units per liter of insulin.
  • ⁇ 5.55 grams of sodium chloride, 3.92 grams of sodium lactate, 0.257 gram of calcium chloride dihydrate, 0.152 gram of magnesium chloride hexahydrate, 1 gram of glucose, 3.25 grams of a mixture of essential and other amino acids, and 3 units per liter of insulin.
  • the various components of the solu- tions may be broken down into two solutions with the glu ⁇ cose being in one portion and the amino acids in the other, for separate sterilization.
  • Each of the solutions may be in a conventional flexible, collapsible container con ⁇ nected by tubing and sealed with any desired internal tubing seal, so that the solution may be separately ster ⁇ ilized. Thereafter, the internal tubing seal may be broken and the solutions may be joined together into the single solution of this invention without disruption of the ster ⁇ ile seal of the solution.
  • the solution container ultimately used to store the mixed, sterile solution of this invention may be stored in a container of the design illustrated, for example, in U.S. Patent No. 4,232,721, being made out of a substantially polypropylene plastic.
  • the connection tube to the other container may be heat-sealed shut and severed after mix ⁇ ing of the containers in conventional manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une solution medicale destinee a etre administree a des patients, et d'une maniere caracteristique une solution de dialyse peritoneale, consiste en une solution aqueuse dans laquelle sont presents des sels physiologiques en concentration suffisante pour avoir une compatibilite osmotique avec le sang. Pour un effet osmotique accru et aussi a des fins de nutrition, un melange d'acides amines, de preference comprenant des acides amines essentiels, de l'insuline et de preference une source de nutrition carbohydratee peut etre present dans des proportions suffisantes pour ameliorer l'assimilation des acides amines et de la source carbohydratee par un patient diabetique, par exemple, ou d'autres patients.
PCT/US1982/000365 1981-04-27 1982-03-25 Solution de dialyse contenant du glucose, des acides amines et de l'insuline WO1982003773A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU83923/82A AU8392382A (en) 1981-04-27 1982-03-25 Dialysis solution containing glucose, amino acids & insulin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25810581A 1981-04-27 1981-04-27
US258105810427 1981-04-27

Publications (1)

Publication Number Publication Date
WO1982003773A1 true WO1982003773A1 (fr) 1982-11-11

Family

ID=22979115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1982/000365 WO1982003773A1 (fr) 1981-04-27 1982-03-25 Solution de dialyse contenant du glucose, des acides amines et de l'insuline

Country Status (6)

Country Link
EP (1) EP0077354A4 (fr)
JP (1) JPS58500563A (fr)
CA (1) CA1168582A (fr)
IT (1) IT1151741B (fr)
WO (1) WO1982003773A1 (fr)
ZA (1) ZA822608B (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3716437A1 (de) * 1986-05-27 1987-12-03 Sandoz Ag Pharmazeutische zusammensetzung
DE3812525C1 (fr) * 1988-04-15 1989-06-22 Fresenius Ag, 6380 Bad Homburg, De
EP0347714A2 (fr) * 1988-06-22 1989-12-27 Fresenius AG Solution de dialyse et de rinçage pour l'administration par voie péritonéale
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
WO1992011773A1 (fr) * 1990-12-31 1992-07-23 University Of Florida Compositions et procedes permettant d'obtenir une reponse physiologique amelioree a l'effort
WO1993007857A1 (fr) * 1991-10-21 1993-04-29 Kabi Pharmacia Gmbh Solution nutritive calorique stabilisee et systeme a chambres multiples pour l'alimentation parenterale de l'homme
US5238684A (en) * 1988-07-29 1993-08-24 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5290766A (en) * 1991-02-18 1994-03-01 The National Heart Foundation Of New Zealand Cardioplegic compositions
GB2292314A (en) * 1994-04-11 1996-02-21 East Wellsum Ind Sweetening agents with amino acids
WO1997006810A1 (fr) * 1995-08-11 1997-02-27 George Wu Solution aqueuse biocompatible a usage en dialyse peritoneale continue ambulatoire
DE19703816A1 (de) * 1996-01-25 1997-08-07 Schering Ag Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung
US5670176A (en) * 1992-12-22 1997-09-23 Baxter International Inc. Amino acid solutions for treatment of peritoneal dialysis patients
EP0827749A2 (fr) † 1992-12-22 1998-03-11 Baxter International Inc. Solution pour dialyse péritonéale
WO1999020249A1 (fr) * 1997-10-16 1999-04-29 Pharmalink Ab Solution destinee a une dialyse perotoneale et son procede de production
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
EP0951915A3 (fr) * 1991-11-18 2001-04-18 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
WO2001035943A3 (fr) * 1999-11-15 2002-03-21 Hanamaraddi T Gangal Preparation de fluides a base de dextrose et d'insuline destinee a une infusion intraveineuse
WO2002049636A1 (fr) * 2000-12-19 2002-06-27 Rajagopal Thiruvengadam Composition antidiabetique a base d'aminoacides
WO2002053094A3 (fr) * 2000-12-28 2002-09-06 Gambro Lundia Ab Procede de detoxification d'une solution contenant un hydrate de carbone
WO2008106702A1 (fr) * 2007-03-02 2008-09-12 Zytoprotec Gmbh Liquide de dialyse péritonéale à base d'hydrate de carbone, comprenant un résidu de glutamine
US8927505B2 (en) 2008-07-07 2015-01-06 Pentec Health, Inc. Nutritive compositions and methods of using same
US9326963B2 (en) 2008-07-07 2016-05-03 Pentec Health, Inc. Nutritive compositions and methods of using same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574085A (en) * 1981-05-15 1986-03-04 Baxter Travenol Laboratories, Inc. Method for using dialysis solution containing glycerol

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738299A (en) * 1953-05-11 1956-03-13 Abbott Lab Stable nutritive amino acid compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920838A (en) * 1973-09-04 1975-11-18 Flatt Jean Pierre Amino acid therapy
US4239041A (en) * 1977-03-03 1980-12-16 Moncrief Jack W Method for continuous ambulatory peritoneal dialysis
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738299A (en) * 1953-05-11 1956-03-13 Abbott Lab Stable nutritive amino acid compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 92, No. 5, published on 4 February 1980 (Columbus, Ohio, USA), K. KOBYASHI et al, "Nitrogen Metabolism in Patients on Peritoneal Dialysis", see page 561, Column 1, Abstract No. 39239; Contrib. Nephrol., 1979 (10) 303-8 (Eng.) *
RAWLINS, Textbook of Pharmaceutics 1977 pgs. 326-329 *
The Lancet, Vol. II, No. 8142, published on 15 September 1979 (Boston, Massachusetts, USA and London England) C. FLYNN et al, "Intraperitoneal Insulin in Diabetes", see page 591, Columns 1 and 2 *

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2190838B (en) * 1986-05-27 1990-12-12 Sandoz Ltd Pharmaceutical compositions
DE3716437A1 (de) * 1986-05-27 1987-12-03 Sandoz Ag Pharmazeutische zusammensetzung
DE3812525C1 (fr) * 1988-04-15 1989-06-22 Fresenius Ag, 6380 Bad Homburg, De
US5011826A (en) * 1988-04-15 1991-04-30 Fresenius Ag Aqueous dialysis and rinsing solution for intraperitoneal administration
EP0347714A2 (fr) * 1988-06-22 1989-12-27 Fresenius AG Solution de dialyse et de rinçage pour l'administration par voie péritonéale
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
EP0347714A3 (fr) * 1988-06-22 1990-12-27 Fresenius AG Solution de dialyse et de rinçage pour l'administration par voie péritonéale
US5238684A (en) * 1988-07-29 1993-08-24 University Of Florida Compositions and methods for achieving improved physiological response to exercise
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
WO1992011773A1 (fr) * 1990-12-31 1992-07-23 University Of Florida Compositions et procedes permettant d'obtenir une reponse physiologique amelioree a l'effort
US5290766A (en) * 1991-02-18 1994-03-01 The National Heart Foundation Of New Zealand Cardioplegic compositions
US5760005A (en) * 1991-10-21 1998-06-02 Pharmacia Gmbh Stabilized caloric nutrient solution and a multicompartmental system or multiple recipient for human parenteral nourishing
EP0602280A1 (fr) * 1991-10-21 1994-06-22 Pharmacia GmbH Solution nutritive calorique stabilisée et dispositif à chambres multiples pour l'alimentation parentérale de l'homme
WO1993007857A1 (fr) * 1991-10-21 1993-04-29 Kabi Pharmacia Gmbh Solution nutritive calorique stabilisee et systeme a chambres multiples pour l'alimentation parenterale de l'homme
EP1114646A3 (fr) * 1991-11-18 2004-01-07 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
EP1114645A3 (fr) * 1991-11-18 2004-01-07 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
EP1114645A2 (fr) * 1991-11-18 2001-07-11 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
EP1114646A2 (fr) * 1991-11-18 2001-07-11 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
EP0951915A3 (fr) * 1991-11-18 2001-04-18 Gambro Lundia AB Système et méthode pour préparer une solution médicale stérile contenant des composés à base de glucose ou similaires
EP0827748A2 (fr) † 1992-12-22 1998-03-11 Baxter International Inc. Solution pour dialyse péritonéale
EP0827749A2 (fr) † 1992-12-22 1998-03-11 Baxter International Inc. Solution pour dialyse péritonéale
US5776503A (en) * 1992-12-22 1998-07-07 Baxter International Inc. Amino acid solutions for treatment of peritoneal dialysis patients
EP0827749B2 (fr) † 1992-12-22 2006-09-27 Baxter International Inc. Solution pour dialyse péritonéale
EP0827748B2 (fr) † 1992-12-22 2006-08-02 Baxter International Inc. Solution pour dialyse péritonéale
US5698230A (en) * 1992-12-22 1997-12-16 Baxter International Inc. Amino acid solutions for treatment of peritoneal dialysis patients
US5670176A (en) * 1992-12-22 1997-09-23 Baxter International Inc. Amino acid solutions for treatment of peritoneal dialysis patients
GB2292314A (en) * 1994-04-11 1996-02-21 East Wellsum Ind Sweetening agents with amino acids
WO1997006810A1 (fr) * 1995-08-11 1997-02-27 George Wu Solution aqueuse biocompatible a usage en dialyse peritoneale continue ambulatoire
DE19703816A1 (de) * 1996-01-25 1997-08-07 Schering Ag Verbesserte konzentrierte Injektions- und Infusionslösungen für die intravasale Anwendung
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
WO1999020249A1 (fr) * 1997-10-16 1999-04-29 Pharmalink Ab Solution destinee a une dialyse perotoneale et son procede de production
WO2001035943A3 (fr) * 1999-11-15 2002-03-21 Hanamaraddi T Gangal Preparation de fluides a base de dextrose et d'insuline destinee a une infusion intraveineuse
WO2002049636A1 (fr) * 2000-12-19 2002-06-27 Rajagopal Thiruvengadam Composition antidiabetique a base d'aminoacides
AU2002217704B2 (en) * 2000-12-28 2006-03-02 Gambro Lundia Ab Method for detoxifying a carbohydrate containing solution
WO2002053094A3 (fr) * 2000-12-28 2002-09-06 Gambro Lundia Ab Procede de detoxification d'une solution contenant un hydrate de carbone
WO2008106702A1 (fr) * 2007-03-02 2008-09-12 Zytoprotec Gmbh Liquide de dialyse péritonéale à base d'hydrate de carbone, comprenant un résidu de glutamine
US9931369B2 (en) 2007-03-02 2018-04-03 Zytoprotec Gmbh Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue
US11534475B2 (en) 2007-03-02 2022-12-27 Zytoprotec Gmbh Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue
US8927505B2 (en) 2008-07-07 2015-01-06 Pentec Health, Inc. Nutritive compositions and methods of using same
US9326963B2 (en) 2008-07-07 2016-05-03 Pentec Health, Inc. Nutritive compositions and methods of using same
US9937125B2 (en) 2008-07-07 2018-04-10 Pentec Health, Inc. Intradialytic parenteral nutrition compositions

Also Published As

Publication number Publication date
CA1168582A (fr) 1984-06-05
EP0077354A1 (fr) 1983-04-27
IT8220921A0 (it) 1982-04-23
JPS58500563A (ja) 1983-04-14
ZA822608B (en) 1983-03-30
IT1151741B (it) 1986-12-24
EP0077354A4 (fr) 1983-09-30

Similar Documents

Publication Publication Date Title
CA1168582A (fr) Solution de glucose, d'acides amines et d'insuline pour dialyse
EP1465688B9 (fr) Solutions a base de bicarbonate pour traitements de dialyse
AU638527B2 (en) Histidine buffered peritoneal dialysis solution
CN101843634B (zh) 含艾考糊精的生物相容性透析流体
US20060226080A1 (en) Bicarbonate-based peritoneal dialysis solutions
US5945449A (en) Sterile bicarbonate concentrate
US4574085A (en) Method for using dialysis solution containing glycerol
US20080044490A1 (en) Sterile low bicarbonate dialysis concentrate solutions
Ing et al. Bicarbonate-buffered peritoneal dialysis
AU8392382A (en) Dialysis solution containing glucose, amino acids & insulin
CA2219822C (fr) Concentre de bicarbonate sterile
Pascual et al. Hemofiltration in children with renal failure
EP3703758A1 (fr) Méthode et système permettant de fournir des fluides de dialyse péritonéale à concentrations de potassium variables
EP3703759A1 (fr) Procédé et système de fourniture de fluides de dialyse péritonéale ayant des concentrations variables de sodium
Guillot et al. Continuous ambulatory peritoneal dialysis in pediatrics: preliminary results on 18 months experience
Bonzel et al. Practical Problems with Continuous Ambulatory Peritoneal Dialysis in Children

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1982901271

Country of ref document: EP

AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): BE CH DE FR GB

WWP Wipo information: published in national office

Ref document number: 1982901271

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1982901271

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载